ATE119771T1 - Behandlung von beschädigtem knochenmark und dosierungseinheiten dafür. - Google Patents

Behandlung von beschädigtem knochenmark und dosierungseinheiten dafür.

Info

Publication number
ATE119771T1
ATE119771T1 AT89911136T AT89911136T ATE119771T1 AT E119771 T1 ATE119771 T1 AT E119771T1 AT 89911136 T AT89911136 T AT 89911136T AT 89911136 T AT89911136 T AT 89911136T AT E119771 T1 ATE119771 T1 AT E119771T1
Authority
AT
Austria
Prior art keywords
bone marrow
pharmaceutically acceptable
damage
aliphatic
substituted
Prior art date
Application number
AT89911136T
Other languages
English (en)
Inventor
Richard F Borch
Therese K Schmalbach
Original Assignee
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rochester filed Critical Univ Rochester
Application granted granted Critical
Publication of ATE119771T1 publication Critical patent/ATE119771T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polishing Bodies And Polishing Tools (AREA)
  • Magnetic Heads (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
AT89911136T 1988-09-12 1989-09-12 Behandlung von beschädigtem knochenmark und dosierungseinheiten dafür. ATE119771T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/243,405 US4938949A (en) 1988-09-12 1988-09-12 Treatment of damaged bone marrow and dosage units therefor

Publications (1)

Publication Number Publication Date
ATE119771T1 true ATE119771T1 (de) 1995-04-15

Family

ID=22918655

Family Applications (1)

Application Number Title Priority Date Filing Date
AT89911136T ATE119771T1 (de) 1988-09-12 1989-09-12 Behandlung von beschädigtem knochenmark und dosierungseinheiten dafür.

Country Status (9)

Country Link
US (1) US4938949A (de)
EP (1) EP0433393B1 (de)
JP (1) JPH04500676A (de)
AT (1) ATE119771T1 (de)
AU (1) AU623184B2 (de)
DE (1) DE68921760D1 (de)
DK (1) DK44791A (de)
NZ (1) NZ230622A (de)
WO (1) WO1990002550A1 (de)

Families Citing this family (646)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187193A (en) * 1988-09-12 1993-02-16 University Of Rochester Method for stimulating transplanted bone marrow cells
AU6647190A (en) * 1989-10-10 1991-05-16 University Of Rochester Method for producing bone marrow growth cell factors
CA2113990A1 (en) * 1991-07-26 1993-02-18 Frederick L. Moolten Cancer therapy utilizing malignant cells
US5240914A (en) * 1992-02-03 1993-08-31 Adolph Schwimmer Method and compositions for inhibiting tumor cell metabolism
US6448235B1 (en) 1994-07-11 2002-09-10 University Of Virginia Patent Foundation Method for treating restenosis with A2A adenosine receptor agonists
US6514949B1 (en) 1994-07-11 2003-02-04 University Of Virginia Patent Foundation Method compositions for treating the inflammatory response
US7135584B2 (en) 1995-08-07 2006-11-14 Wake Forest University Lipid analogs for treating viral infections
JP4259611B2 (ja) * 1994-08-29 2009-04-30 ウェイク フォレスト ユニバーシティ ウィルス感染を治療するための脂質アナログ
US5807874A (en) * 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US5767142A (en) * 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US5616575A (en) * 1995-12-04 1997-04-01 Regents Of The University Of Minnesota Bioactive tricyclic ibogaine analogs
US5932553A (en) * 1996-07-18 1999-08-03 The Regents Of The University Of California Illudin analogs useful as antitumor agents
US5723632A (en) 1996-08-08 1998-03-03 Mgi Pharma, Inc. Total synthesis of antitumor acylfulvenes
US5922761A (en) * 1996-09-06 1999-07-13 Medinox, Inc. Methods for in vivo reduction of iron levels and compositions useful therefor
US5981541A (en) * 1996-09-23 1999-11-09 Rutgers, The State University Of New Jersey Substituted heterocycles as anti-tumor agents
US5916903A (en) * 1997-02-28 1999-06-29 Synapse Pahrmaceuticals International, Inc. Method for reducing the effects of antineoplastic disease treatment
US5866558A (en) * 1997-05-08 1999-02-02 Regents Of The University Of Minnesota 6-alkynyl steroids
US6486214B1 (en) 1997-09-10 2002-11-26 Rutgers, The State University Of New Jersey Polyanhydride linkers for production of drug polymers and drug polymer compositions produced thereby
US6468519B1 (en) 1997-09-10 2002-10-22 Rutgers, The State University Of New Jersey Polyanhydrides with biologically active degradation products
US6140328A (en) * 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
ATE219085T1 (de) * 1997-12-29 2002-06-15 Res Corp Technologies Inc 2-beta-substituierte-6-alkylidenpenizillansäure derivate als beta-laktamase inhibitoren
US6051603A (en) * 1998-01-20 2000-04-18 Wayne Hughes Institute Vanadium (IV) metallocene complexes having sperm motility inhibiting activity
US6245808B1 (en) 1998-11-05 2001-06-12 Parker Hughes Institute Oxy-vanadium (IV) complexes having spermicidal activity
US6432941B1 (en) * 1998-01-20 2002-08-13 Parker Hughes Institute Vanadium compounds for treating cancer
IL137351A0 (en) 1998-02-12 2001-07-24 Univ Rutgers Heterocyclic topoisomerase poisons
US6025328A (en) 1998-02-20 2000-02-15 The Regents Of The University Of California Antitumor agents
US7141603B2 (en) * 1999-02-19 2006-11-28 The Regents Of The University California Antitumor agents
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
US6355678B1 (en) * 1998-06-29 2002-03-12 Parker Hughes Institute Inhibitors of the EGF-receptor tyrosine kinase and methods for their use
US6800649B1 (en) 1998-06-30 2004-10-05 Parker Hughes Institute Method for inhibiting c-jun expression using JAK-3 inhibitors
US6323190B1 (en) 1998-07-31 2001-11-27 The Univeristy Of Georgia Research Foundation, Inc. Estrogen mimetics lacking reproductive tract effects
US7427606B2 (en) * 1999-02-01 2008-09-23 University Of Virginia Patent Foundation Method to reduce inflammatory response in transplanted tissue
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
US6232297B1 (en) 1999-02-01 2001-05-15 University Of Virginia Patent Foundation Methods and compositions for treating inflammatory response
US6166003A (en) * 1999-02-17 2000-12-26 Lkt Laboratories, Inc. Heterocyclic compounds for cancer chemoprevention
US6638518B1 (en) 1999-02-22 2003-10-28 University Of Iowa Research Foundation Method for inhibiting inflammatory responses
US6080747A (en) 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
KR20010102543A (ko) 1999-03-09 2001-11-15 로렌스 티. 마이젠헬더 항바이러스제로서의4-옥소-4,7-디히드로-티에노[2,3-b]피리딘-5-카르복스아미드
US6306897B1 (en) 1999-03-19 2001-10-23 Parker Hughes Institute Calanolides for inhibiting BTK
US7064114B2 (en) * 1999-03-19 2006-06-20 Parker Hughes Institute Gel-microemulsion formulations
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
US6407091B1 (en) * 1999-04-15 2002-06-18 Research Corporation Technologies, Inc. β-lactamase inhibiting compounds
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US6322771B1 (en) 1999-06-18 2001-11-27 University Of Virginia Patent Foundation Induction of pharmacological stress with adenosine receptor agonists
AU5630800A (en) 1999-06-22 2001-01-09 Arno F Spatola Antimicrobial agents
US6946458B2 (en) 1999-07-22 2005-09-20 University Of South Florida N-thiolated beta-lactams: novel antibacterial agents for methicillin-resistant Staphylococcus aureus
US7151100B1 (en) * 1999-07-23 2006-12-19 The Regents Of The University Of California Indole compounds useful for the treatment of cancer
US6852685B1 (en) 1999-08-17 2005-02-08 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof to promote neuronal cell differentiation
US7119064B2 (en) * 1999-08-17 2006-10-10 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof as modulators of intracellular signaling molecules
US6903068B1 (en) 1999-08-17 2005-06-07 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof for inducing cytokines
US6500798B1 (en) 1999-08-17 2002-12-31 Board Of Regents, The University Of Texas System Use of colostrinin, constituent peptides thereof, and analogs thereof, as oxidative stress regulators
MY125942A (en) 1999-09-07 2006-09-29 Upjohn Co Aminoalkoxy carbazoles for the treatment of cns diseases
US6670341B1 (en) 1999-10-28 2003-12-30 Wake Forest University Health Sciences Compositions and methods for double-targeting virus infections and targeting cancer cells
US7026469B2 (en) 2000-10-19 2006-04-11 Wake Forest University School Of Medicine Compositions and methods of double-targeting virus infections and cancer cells
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
WO2001036431A1 (en) 1999-11-15 2001-05-25 Parker Hughes Institute Diamino platinum (ii) antitumor complexes
US6649654B1 (en) 1999-11-23 2003-11-18 The Regents Of The University Of California Methods for identifying and using IKK inhibitors
US6589992B2 (en) 1999-11-30 2003-07-08 Parker Hughes Institute Inhibiting collagen-induced platelet aggregation
US20040038948A1 (en) * 1999-12-07 2004-02-26 Uhrich Kathryn E. Therapeutic compositions and methods
US6685928B2 (en) 1999-12-07 2004-02-03 Rutgers, The State University Of New Jersey Therapeutic compositions and methods
EP1252181B1 (de) * 2000-01-20 2006-01-18 Regents Of The University Of Minnesota Peptide mit antibakterieller wirkung
KR20020081480A (ko) 2000-03-21 2002-10-26 파마시아 앤드 업존 캄파니 항바이러스제로서의 4-히드록시신놀린-3-카르복시아미드
KR20030013378A (ko) 2000-03-21 2003-02-14 파마시아 앤드 업존 캄파니 항바이러스제로서의4-히드록시-1,8-나프티리딘-3-카르복스아미드
WO2001074816A1 (en) 2000-03-21 2001-10-11 Pharmacia & Upjohn Company 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents
US6682892B2 (en) * 2000-07-13 2004-01-27 Pharmacia & Upjohn Company Method for treating herpes viruses
US20040152672A1 (en) * 2000-08-09 2004-08-05 Carson Dennis A. Indole compounds useful for the treatment of cancer
US6696441B1 (en) 2000-08-11 2004-02-24 The Regents Of The University Of California Inhibition of p53-induced stress response
US6951847B2 (en) * 2000-09-29 2005-10-04 Regents Of The University Of Minnesota Methods of treating fungal infections using lupeol
AU2001294953A1 (en) 2000-09-29 2002-04-08 Regents Of The University Of Minnesota Triterpenes having fungicidal activity against yeast
US6689767B2 (en) 2000-09-29 2004-02-10 Regents Of The University Of Minnesota Triterpenes having antibacterial activity
US7309696B2 (en) 2000-10-19 2007-12-18 Wake Forest University Compositions and methods for targeting cancer cells
US6958359B1 (en) 2000-11-15 2005-10-25 Parker Hughes Institute Vanadium compounds as anti-angiogenic agents
US6642221B1 (en) 2000-11-15 2003-11-04 Parker Hughes Institute Vanadium compounds as anti-proliferative agents
US6878388B1 (en) 2000-11-15 2005-04-12 Parker Hughes Institute Vanadium compounds for treating proliferative cell disorders
US6630462B2 (en) 2000-11-17 2003-10-07 Adolor Corporation Delta agonist analgesics
US20040034045A1 (en) * 2000-11-29 2004-02-19 Parker Hughes Institute Inhibitors of thrombin induced platelet aggregation
WO2002060936A2 (en) * 2001-01-31 2002-08-08 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US7261901B2 (en) * 2001-01-31 2007-08-28 University Of Iowa Research Foundation Vaccine and compositions for the prevention and treatment of neisserial infections
US6703524B2 (en) * 2001-02-20 2004-03-09 Lkt Laboratories, Inc. Organoselenium compounds for cancer chemoprevention
US7232829B2 (en) * 2001-04-06 2007-06-19 Regents Of The University Of Minnesota Therapeutic compounds and methods
GB0111872D0 (en) * 2001-05-15 2001-07-04 Northwick Park Inst For Medica Therapeutic agents and methods
CN1486289A (zh) * 2001-05-29 2004-03-31 皇家菲利浦电子有限公司 金属-陶瓷的结合
US7601846B2 (en) * 2001-06-26 2009-10-13 The Regents Of The University Of California Compounds having activity as inhibitors of apoptosis
US20030232794A1 (en) * 2001-06-26 2003-12-18 Cottam Howard B. Use of STAT-6 inhibitors as therapeutic agents
CA2454413A1 (en) * 2001-07-24 2003-03-13 Alamx, L.L.C. 7-alkylidene-3-substituted-3-cephem-4-carboxylates as beta-lactamase inhibitors
US6753414B2 (en) * 2001-08-07 2004-06-22 University Of Iowa Research Foundation, Inc. Process for preparing saponin compounds
CA2453537A1 (en) 2001-08-08 2003-02-20 Pharmacia & Upjohn Company Therapeutic 1h-pyrido¬4,3-b|indoles
US20030171377A1 (en) * 2001-08-29 2003-09-11 Bigge Christopher Franklin Antidiabetic agents
WO2003020728A1 (en) 2001-08-30 2003-03-13 Pharmacia & Upjohn Company 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS
KR100871648B1 (ko) * 2001-08-31 2008-12-03 톰슨 라이센싱 조건부 액세스 시스템을 구현하는 방법, 컨텐트를 전송하는 방법 및 그 장치 및 컨텐트를 수신하고 처리하는 방법 및 그 장치
BR0212676A (pt) * 2001-09-21 2006-05-23 Upjohn Co compostos terapêuticos ligantes de 5-ht, composições farmacêuticas compreendendo tais compostos e seus usos
CA2459125A1 (en) 2001-09-26 2003-04-03 Theravance, Inc. Substituted phenol compounds useful for anesthesia and sedation
NZ556354A (en) * 2001-10-01 2008-10-31 Univ Virginia 2-Propynyl adenosine analogs having A2A agonist activity and compositions thereof
US20030143199A1 (en) * 2001-10-09 2003-07-31 Carson Dennis A. Use of STAT-6 inhibitors as therapeutic agents
AU2002350623A1 (en) * 2001-10-26 2003-05-06 The Scripps Research Institute Targeted thrombosis by tissue factor polypeptides
WO2003041660A2 (en) 2001-11-14 2003-05-22 Rutgers, The State University Solubilized topoisomerase poisons
ES2311639T3 (es) * 2001-11-14 2009-02-16 Rutgers, The State University Agentes citotoxicos.
DE60231555D1 (de) 2001-11-23 2009-04-23 Theodore James Anastasiou Verbesserte synthese von polyanhydriden
US7030141B2 (en) * 2001-11-29 2006-04-18 Christopher Franklin Bigge Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade
EP1517689A2 (de) * 2002-01-25 2005-03-30 Regents Of The University Of Minnesota Selektive analgetika
US7968605B2 (en) * 2002-02-04 2011-06-28 ALFAMA—Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda. Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
NZ534912A (en) * 2002-02-04 2007-08-31 Alfama Investigacao E Desenvol supramolecule aggregate comprising CO containing organometallic or transition metal complex and anti-inflammatory agent or biphosphonate phosphonate derivative
US20080026984A1 (en) * 2002-02-04 2008-01-31 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Methods for treating inflammatory disease by administering aldehydes and derivatives thereof
CN1646068A (zh) 2002-02-07 2005-07-27 拉特格斯,新泽西州立大学 治疗用的聚酯和聚酰胺
AU2003216400A1 (en) 2002-02-22 2003-09-09 The Curators Of The University Of Missouri Compounds for treatment of copper overload
US20050032713A1 (en) * 2002-03-27 2005-02-10 Wurtman Richard J. Platelet-activating factor antagonists as analgesic, anti-inflammatory, uterine contraction inhibiting, and anti-tumor agents
WO2003087105A1 (en) * 2002-04-04 2003-10-23 Alamx, L.L.C. INHIBITORS OF SERINE AND METALLO-ß-LACTAMASES
AU2003223718B2 (en) * 2002-04-25 2007-08-16 The Scripps Research Institute Treatment and prevention of pulmonary conditions
US7026472B2 (en) * 2002-05-06 2006-04-11 University Of South Florida Methods for preventing and treating cancer using N-thiolated β-lactam compounds and analogs thereof
US20040156799A1 (en) * 2002-06-04 2004-08-12 Zigang Dong Cancer treatment method and compositions
UA79293C2 (en) * 2002-07-03 2007-06-11 Univ Wayne State 4-(7'-halo-2-quino (xa-) linyloxy)phenoxy propionic acid derivatives as antineoplastic agents
US20060093595A1 (en) * 2002-07-05 2006-05-04 Mahesh Jayachandra Methods, compositions and kits for treating damage to excitable tissue
WO2004014918A1 (en) * 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted topoisomerase agents
BR0314219A (pt) * 2002-09-11 2005-07-19 Warner Lambert Co Inibidores do fator xa e outras serina proteases envolvidas na cascata da coagulação
AU2003295336A1 (en) * 2002-09-19 2004-04-08 Dennis A. Carson Use of etodoclac to treat hyperplasia
EP2447278B1 (de) 2002-10-10 2015-04-08 Cornell Research Foundation, Inc. Neue immunogene Proteine von Leptospira
US20060183106A1 (en) * 2002-10-18 2006-08-17 Adam Siddiqui-Jain Processes for identifying quadruplex-targeted antiviral molecules
AU2003301559A1 (en) * 2002-10-22 2004-05-13 Board Of Regents The University Of Texas System Colostrinin and peptides thereof as modulators of intracellular signaling molecules and inhibitors of apoptosis
US20040087553A1 (en) * 2002-10-28 2004-05-06 Paraquest, Inc. Hypoestoxides, derivatives and agonists thereof for use in the treatment and prophylaxis of hyperlipidemia
EP1900753B1 (de) 2002-11-08 2017-08-09 Ablynx N.V. Verfahren zur Verabreichung therapeutischer Polypeptide und Polypeptide dafür
EP1558645B1 (de) 2002-11-08 2011-07-27 Ablynx N.V. Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
GB2395432B (en) * 2002-11-20 2005-09-14 Northwick Park Inst For Medica Therapeutic delivery of carbon monoxide to extracorporeal and isolated organs
AU2003298738A1 (en) * 2002-11-26 2004-06-18 Su-Ming Chiang Liposomal formulations
AU2003296944A1 (en) * 2002-12-10 2004-06-30 George Koob A method for treatment of drug addiction and for screening of pharmaceutical agents therefor
US7297340B2 (en) * 2003-01-07 2007-11-20 University Of Iowa Research Foundation Vaccine and method for preventing biofilm formation
JP2006517789A (ja) 2003-01-10 2006-08-03 アブリンクス エン.ヴェー. 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用
US20070207217A1 (en) * 2003-02-03 2007-09-06 Alfama - Investigacao E Desenvolvimento De Productos Farmaceuticos Lda Method for treating a mammal by administration of a compound having the ability to release CO
US20050079512A1 (en) * 2003-02-26 2005-04-14 Emerson Beverly M. Methods of modulating gene expression
US7943800B2 (en) 2003-03-28 2011-05-17 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
US7354916B2 (en) * 2003-04-07 2008-04-08 Cylene Pharmaceuticals Substituted quinobenzoxazine analogs
BRPI0409105A (pt) * 2003-04-07 2006-04-25 Cylene Pharmaceuticals Inc análogos de quinobenzoxazina substituìdos
WO2004091627A2 (en) * 2003-04-07 2004-10-28 Cylene Pharmaceuticals, Inc. Heterocyclic substituted 1,4-dihydro-4-oxo-1,8-naphthpyridine analogs
US7507727B2 (en) * 2003-04-07 2009-03-24 Cylene Pharmaceuticals, Inc. Substituted quinobenzoxazine analogs and methods of using thereof
US20040248880A1 (en) * 2003-04-25 2004-12-09 Jacobsen Eric Jon 1,2,3,4,5,6-Hexahydroazepino[4,5-B]indoles containing arylsulfones at the 9-position
AU2004248138B2 (en) * 2003-05-29 2009-09-03 The Scripps Research Institute Targeted delivery to legumain-expressing cells
JP2007524633A (ja) 2003-06-25 2007-08-30 ザ バーナム インスティチュート 癌細胞におけるアポトーシスの誘導のための化合物および方法
WO2005003140A1 (en) * 2003-07-02 2005-01-13 Pharmacia & Upjohn Company Llc 4-oxo-4,7-dihydrothieno[2,3-b]pyridine-5-carboxamides as antiviral agents
KR101222364B1 (ko) 2003-08-25 2013-01-15 트로비스 파마슈티칼스 엘엘씨 치환된 8-헤테로아릴 크산틴
US7850970B2 (en) 2003-08-26 2010-12-14 The Regents Of The University Of Colorado Inhibitors of serine protease activity and their use in methods and compositions for treatment of bacterial infections
WO2005020928A2 (en) 2003-08-29 2005-03-10 The Regents Of The University Of California Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins
JP2007512234A (ja) * 2003-10-17 2007-05-17 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 治療活性を有する修飾ポリペプチド及びその使用方法
ATE485307T1 (de) 2003-11-07 2010-11-15 Ablynx Nv Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung
EP1694314A4 (de) * 2003-12-04 2009-07-01 Scripps Research Inst Behandlung und prävention von asthma
ATE502298T1 (de) * 2003-12-19 2011-04-15 Univ California Verfahren und materialien zur beurteilung von prostatakrebstherapien
AU2005206163B2 (en) 2004-01-14 2011-06-30 Gilead Sciences, Inc. Lipid-based dispersions useful for drug delivery
WO2005072766A2 (en) * 2004-01-27 2005-08-11 Boys Town National Research Hospital Peptides that bind to hsp90 proteins
US8841326B2 (en) 2004-02-12 2014-09-23 Stc.Unm Therapeutic curcumin derivatives
US20050187191A1 (en) * 2004-02-20 2005-08-25 Kucera Louis S. Methods and compositions for the treatment of respiratory syncytial virus
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
NZ550102A (en) * 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
MXPA06011219A (es) 2004-03-29 2007-05-08 Univ South Florida Tratamiento efectivo de tumores y cancer con triciribina y compuestos relacionados.
JP5149001B2 (ja) * 2004-05-25 2013-02-20 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ 癌の処置におけるマイグラスタチンアナログ
US7576069B2 (en) * 2004-08-02 2009-08-18 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
AU2005267706B2 (en) * 2004-08-02 2011-12-08 University Of Virginia Patent Foundation 2-propynyl adenosine analogs with modified 5'-ribose groups having A2A agonist activity
WO2006023272A1 (en) * 2004-08-02 2006-03-02 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having a2a agonist activity
ES2517840T3 (es) * 2004-08-25 2014-11-04 University Of Iowa Research Foundation Inhibidores de la geranilgeranil pirofosfato sintasa
US20080213345A1 (en) * 2004-09-13 2008-09-04 Gilead Sciences, Inc. Delivering Iron to an Animal
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
US8188141B2 (en) * 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
WO2006040153A2 (en) * 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
US8697674B2 (en) * 2004-12-29 2014-04-15 Naturon, Inc. Xanthurenic acid derivative pharmaceutical compositions and methods related thereto
WO2006086103A2 (en) * 2005-01-10 2006-08-17 University Of Virginia Patent Foundation Synthesis of inhibitors of p90rsk
US7691364B2 (en) * 2005-01-28 2010-04-06 Bezwada Biomedical, Llc Functionalized drugs and polymers derived therefrom
NZ564223A (en) 2005-05-13 2011-03-31 Univ California Diarylhydantoin compounds for treating hormone refractory prostate cancer
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US8188223B2 (en) 2005-05-18 2012-05-29 Ablynx N.V. Serum albumin binding proteins
ES2694247T3 (es) 2005-05-20 2018-12-19 Ablynx N.V. NanobodiesTM mejorados para el tratamiento de trastornos mediados por agregación
US20070025910A1 (en) 2005-07-29 2007-02-01 Norenberg Jeffrey P Anticancer therapy
WO2007019308A2 (en) * 2005-08-03 2007-02-15 The Regents Of The University Of California Illudin analogs useful as anticancer agents
CN101304748A (zh) 2005-08-22 2008-11-12 加利福尼亚大学董事会 Tlr激动剂
JP5259408B2 (ja) 2005-08-29 2013-08-07 ユニバーシティ オブ バージニア パテント ファンデーション リソフィリン類縁体とその使用方法
US8871764B2 (en) 2005-08-29 2014-10-28 University Of Virginia Patent Foundation Lisofylline analogs and methods for use
EP1951260A4 (de) 2005-10-21 2009-11-11 Bezwada Biomedical Llc Funktionalisierte phenolische verbindungen und saugfähiger artikel daraus
US20090291437A1 (en) * 2005-11-02 2009-11-26 O'brien Sean Methods for targeting quadruplex sequences
EP1957112A2 (de) 2005-11-21 2008-08-20 Pietro Paolo Sanna Rolle von proteoglykanen bei drogenabhängigkeit
CN101374856A (zh) * 2005-11-29 2009-02-25 斯克里普斯研究学院 抑制肿瘤细胞浸润、转移和血管生成
US8007526B2 (en) 2005-12-01 2011-08-30 Bezwada Biomedical, Llc Difunctionalized aromatic compounds and polymers therefrom
US20070161546A1 (en) * 2005-12-15 2007-07-12 Colm King Methods and compositions for treatment of cancer
US20070244057A1 (en) * 2006-01-20 2007-10-18 Henry Paulson Suppressing polyglutamine aggregation and toxicity
GB0601394D0 (en) 2006-01-24 2006-03-01 Hemocorm Ltd Therapeutic delivery of carbon monoxide
US7615649B2 (en) * 2006-01-26 2009-11-10 Iowa State University Research Foundation, Inc, Synthesis of polycyclic procyanidins
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
WO2007098139A2 (en) * 2006-02-21 2007-08-30 The Ohio State University Research Foundation Anticancer agents
CA2643732C (en) 2006-02-27 2012-08-21 The Regents Of The University Of California Oxysterol compounds and the hedgehog pathway
NZ570847A (en) 2006-02-28 2011-10-28 Helicon Therapeutics Inc Therapeutic compounds
EP2007383A4 (de) * 2006-03-22 2010-09-15 Univ California Hemmer von protein-prenyltransferasen
SI2656842T1 (sl) 2006-03-27 2016-10-28 The Regents Of The University Of California Modulator androgenih receptorjev za zdravljenje raka prostate in bolezni, povezanih z androgenimi receptorji
WO2007127010A2 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
US8093235B2 (en) 2006-04-25 2012-01-10 Rutgers, The State University Of New Jersey Macrocyclic compounds which stabilize G-Quadruplex DNA and RNA
WO2007139778A2 (en) * 2006-05-22 2007-12-06 University Of Virginia Patent Foundation Rhamnose substituents of sl0101 and therapeutic uses thereof
EP2700638A1 (de) 2006-05-31 2014-02-26 The Regents Of the University of California Purinanaloga
WO2007143081A2 (en) * 2006-06-02 2007-12-13 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
WO2007146831A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Quinolone analogs derivatized with sulfonic acid, sulfonate or sulfonamide
WO2007146813A2 (en) * 2006-06-08 2007-12-21 Cylene Pharmaceuticals, Inc. Pyridinone analogs as cell proliferation inhibitors
WO2007149277A2 (en) 2006-06-16 2007-12-27 Pgx Health, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US8188063B2 (en) * 2006-06-19 2012-05-29 University Of Virginia Patent Foundation Use of adenosine A2A modulators to treat spinal cord injury
WO2008034019A2 (en) 2006-09-13 2008-03-20 Polymerix Corporation Active agents and their oligomers and polymers
US20080206287A1 (en) * 2006-09-18 2008-08-28 Reed John C Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands
US8022246B2 (en) * 2006-10-10 2011-09-20 The Burnham Institute For Medical Research Neuroprotective compositions and methods
US8034829B2 (en) 2006-11-17 2011-10-11 Rexahn Pharmaceuticals, Inc. 5, 6, or 7-substituted-3-(hetero)arylisoquinolinamine derivatives and therapeutic use thereof
EP2086962A1 (de) * 2006-11-29 2009-08-12 Pfizer Products Inc. (r)-5-methyl-4,5-dihydropyrazol-1,5-dicarbonsäure-1-[(4-chlorphenyl)amid-5-{[2-fluor-4-(2-oxo-2h-pyridin-1-yl)phenyl]amid) als faktor-xa-inhibitor
CA2673331A1 (en) 2006-12-19 2008-06-26 Ablynx N.V. Amino acid sequences directed against gpcrs and polypeptides comprising the same for the treatment of gpcr-related diseases and disorders
EP2102244A2 (de) 2006-12-19 2009-09-23 Ablynx N.V. Gegen metalloproteinase aus der adam-familie gerichtete aminosäuresequenzen und diese enthaltende polypeptide zur behandlung von mit adam in zusammenhang stehenden krankheiten und störungen
JP2010518108A (ja) 2007-02-06 2010-05-27 ユニバーシティ オブ ルーイビル リサーチ ファウンデーション,インコーポレーテッド 治療化合物
CN101790380B (zh) 2007-02-07 2013-07-10 加利福尼亚大学董事会 合成tlr激动剂的缀合物及其应用
WO2008103818A1 (en) * 2007-02-21 2008-08-28 University Of Louisville Research Foundation Therapeutic cotinine compositions
EP2132183B1 (de) 2007-02-28 2015-06-03 University Of Virginia Patent Foundation Lisofyllinanaloga und anwendungsverfahren
US8569449B2 (en) 2007-05-08 2013-10-29 University Of Louisville Research Foundation, Inc. Synthetic peptides and peptide mimetics
CA2695330C (en) 2007-07-12 2017-06-13 University Of South Florida Inhibitors of akt/pkb with anti-tumor activity
JP2010535204A (ja) 2007-08-02 2010-11-18 ラトガーズ, ザ ステイト ユニバーシティ オブ ニュー ジャージー 治療用化合物
WO2009025797A1 (en) * 2007-08-16 2009-02-26 Burnham Institute For Medical Research Compositions and methods for treating symptoms of aging
KR101669432B1 (ko) 2007-08-27 2016-10-26 다트 뉴로사이언스 (케이만) 엘티디. 치료적 이속사졸 화합물
US8217134B2 (en) 2007-08-30 2012-07-10 Bezwada Biomedical, Llc Controlled release of biologically active compounds
US8048980B2 (en) 2007-09-17 2011-11-01 Bezwada Biomedical, Llc Hydrolysable linkers and cross-linkers for absorbable polymers
US7928100B2 (en) 2007-10-05 2011-04-19 Cylene Pharmaceuticals, Inc. Quinolone analogs and methods related thereto
EP2205088B1 (de) 2007-10-19 2018-02-21 Burnham Institute for Medical Research Auf naphthalin basierende hemmer von anti-apoptotischen proteinen
US8039668B2 (en) 2008-10-17 2011-10-18 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
WO2009055677A1 (en) * 2007-10-24 2009-04-30 University Of South Florida Antibacterial s-heterosubstituted disulfides
EP2620432A3 (de) 2007-10-26 2013-12-18 The Regents Of the University of California Diarylhydantoinverbindungen
US7951832B2 (en) * 2007-10-31 2011-05-31 Burnham Institute For Medical Research Pyrazole derivatives as kinase inhibitors
CN101951915A (zh) 2007-12-03 2011-01-19 加利福尼亚大学董事会 用于刺猬蛋白信号、骨诱导、抗脂肪形成和wnt信号的激活的氧固醇
US8058259B2 (en) * 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EA201001264A1 (ru) * 2008-02-07 2011-04-29 Дзе Регентс Оф Дзе Юниверсити Оф Калифорния Способ лечения заболеваний мочевого пузыря с помощью активатора tlr7
US8142764B2 (en) 2008-02-27 2012-03-27 University Of Louisville Research Foundation Synthetic biofilm-inhibiting peptides
US20090247466A1 (en) * 2008-03-10 2009-10-01 University Of Louisville Research Foundation Neuroprotective integrin-binding peptide and angiopoietin-1 treatments
US20110046101A1 (en) * 2008-03-17 2011-02-24 Dmitrienko Gary I Bate-lactamase inhibitors
WO2009146112A1 (en) * 2008-04-02 2009-12-03 University Of Virginia Patent Foundation Compositions and methods for inhibiting sphingosine kinase
JP2011516520A (ja) 2008-04-07 2011-05-26 アブリンクス エン.ヴェー. Notch経路に指向性を有するアミノ酸配列及びその使用
EP2285833B1 (de) 2008-05-16 2014-12-17 Ablynx N.V. Gegen cxcr4 und andere gpcr gerichtete aminosäuresequenzen sowie verbindungen damit
US9872867B2 (en) * 2008-06-06 2018-01-23 Tanya Kuritz Methods and compositions for modulation of innate immunity
WO2009153782A1 (en) 2008-06-17 2009-12-23 Ben Gurion University Of The Negev R&D Authority Substituted cyclohexylidene-ethylidene-octahydro-indene compounds
US8673910B2 (en) * 2008-06-30 2014-03-18 H. Lee Moffitt Cancer Center And Research Institute Proteasome inhibitors for selectively inducing apoptosis in cancer cells
US7947717B2 (en) * 2008-07-18 2011-05-24 Burnham Institute For Medical Research Inhibitors of lethal factor protease
US9125821B2 (en) 2008-07-28 2015-09-08 The Regents Of The University Of California Nanodrug targeting protein geranylgeranylation
US20110178138A1 (en) * 2008-07-28 2011-07-21 The Regents Of The University Of California Inhibitors of protein prenyltransferases
CA2733126A1 (en) 2008-08-05 2010-02-11 University Of South Florida Methods of treating cognitive impairment
US9132168B2 (en) 2008-08-05 2015-09-15 University Of South Florida Methods of treating cognitive impairment
US8871983B2 (en) * 2008-08-08 2014-10-28 University Of Florida Research Foundation, Inc. Lipid compounds for suppression of tumorigenesis
US9801865B2 (en) * 2008-09-24 2017-10-31 The United States Of America As Represented By The Department Of Veteran Affairs Materials and methods for diagnosis, prevention and/or treatment of stress disorders and conditions associated with abeta peptide aggregation
US8124654B2 (en) * 2008-11-11 2012-02-28 Immune Modulation, Inc. Derivatives of hypoestoxide and related compounds
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
WO2010088924A1 (en) 2009-02-06 2010-08-12 Telormedix Sa Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration
KR20110117705A (ko) 2009-02-11 2011-10-27 더 리전트 오브 더 유니버시티 오브 캘리포니아 톨-유사 수용체 조정제 및 질병의 치료
DK2403856T3 (da) 2009-03-06 2013-04-08 Univ Rutgers Methylendioxybenzo[i]phenanthridinderivater anvendt til behandling af cancer
EP2408447A1 (de) 2009-03-20 2012-01-25 University of Iowa Research Foundation Prenylierte bisphosphonate als anti-tuberkulose-mittel
NZ595461A (en) 2009-04-10 2013-01-25 Ablynx Nv Improved amino acid sequences directed against il-6r and polypeptides comprising the same for the treatment of il-6r related diseases and disorders
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
US20120108823A1 (en) 2009-04-22 2012-05-03 The Ohio State University Research Foundation Anti-francisella agents
US8906965B2 (en) 2009-05-11 2014-12-09 The University Of Tennessee Research Foundation Anti-inflammatory quinic acid derivatives for radioprotection/radiomitigation
EP2430016B1 (de) 2009-05-13 2020-04-01 University Of Virginia Patent Foundation Hemmer der inv(16)-leukämie
BRPI1014224A2 (pt) 2009-06-30 2019-09-24 Forest Laboratories Holdings Ltd composto, composição farmacêutica,e, método para tratar um estado.
WO2011005871A1 (en) 2009-07-07 2011-01-13 Pgxhealth, Llc Substituted 8-[6-carbonylamine-3-pyridyl]xanthines as adenosine a2b antagonists
RU2012104552A (ru) 2009-07-09 2013-08-20 СиБиТи ДЕВЕЛОПМЕНТ ЛИМИТЕД Комбинированный препарат для применения в качестве лекарственного средства
TW201107330A (en) 2009-07-31 2011-03-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
WO2011019995A2 (en) 2009-08-14 2011-02-17 Hecht Sidney M Synthesis and identification of novel rsk-specific inhibitors
TW201111385A (en) 2009-08-27 2011-04-01 Biocryst Pharm Inc Heterocyclic compounds as janus kinase inhibitors
US8642088B2 (en) 2009-09-04 2014-02-04 Wisconsin Alumni Research Foundation Tannin-chitosan composites
EP2473041B1 (de) 2009-09-04 2018-03-07 Merck Sharp & Dohme Corp. Modulatoren von zellzyklus-kontrollpunkten und ihre verwendung in kombination mit kontrollpunkt-kinasehemmern
AU2010303324A1 (en) * 2009-10-08 2012-04-05 Sanford-Burnham Medical Research Institute Apogossypolone derivatives as anticancer agents
EP2496704A4 (de) 2009-11-05 2013-05-01 Univ Rutgers Therapeutische verbindungen
US8598235B2 (en) 2009-12-04 2013-12-03 Jon E. Grant Treating impulse control disorders with catechol-O-methyl-transferase inhibitors
US9096544B2 (en) 2009-12-23 2015-08-04 Wayne State University Therapeutic compounds
CN102762571A (zh) 2009-12-23 2012-10-31 拜奥克里斯特制药公司 作为janus激酶抑制剂的杂环化合物
AU2011218173C1 (en) 2010-02-16 2015-04-16 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
EP2539348A4 (de) 2010-02-26 2013-07-24 Gary Igor Dmitrienko Cephalosporinderivate als beta-lactamase-hemmer sowie zusammensetzungen damit und verfahren zu ihrer anwendung
JP2013523748A (ja) 2010-03-29 2013-06-17 サーモディクス,インコーポレイテッド 注射用薬物送達製剤
WO2011123856A1 (en) 2010-04-02 2011-10-06 Tsrl, Inc. Neuraminidase inhibitors
WO2011127344A2 (en) 2010-04-08 2011-10-13 University Of Virginia Patent Foundation Method to detect and treat infectious or inflammatory diarrhea
WO2011130740A2 (en) 2010-04-16 2011-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Pyridylthiazole-based ureas as inhibitors of rho associated protein kinase (rock) and methods of use
WO2011133696A2 (en) 2010-04-20 2011-10-27 Regents Of The University Of Minnesota Methods of suppressing atherosclerosis
MX2012013824A (es) 2010-05-28 2013-03-12 Biocryst Pharm Inc Compuestos heterociclicos como inhibidores de cinasa janus.
WO2011156626A1 (en) 2010-06-09 2011-12-15 Rutgers, The State University Of New Jersey Antimicrobial agents
CA2803890A1 (en) 2010-06-25 2011-12-29 Rutgers, The State University Of New Jersey Antimicrobial agents
US8741317B2 (en) 2010-08-19 2014-06-03 Rutgers, The State University Of New Jersey Slow-degrading polymers comprising salicylic acid for undelayed and sustained drug delivery
WO2012027494A1 (en) 2010-08-24 2012-03-01 Regents Of The University Of Minnesota Bispecific targeting reagents
WO2012038058A1 (en) 2010-09-21 2012-03-29 Telormedix Sa Treatment of conditions by toll-like receptor modulators
CN103491978A (zh) 2010-10-25 2014-01-01 明尼苏达大学评议会 用于治疗成胶质细胞瘤的治疗组合物
WO2012058665A1 (en) 2010-10-29 2012-05-03 University Of Connecticut Compositions and methods for modulation and detection of immune and inflammatory responses
EP3363435A1 (de) 2010-11-01 2018-08-22 The Ohio State University Research Foundation Celecoxibderivate gegen staphylokokken
AU2011326034B2 (en) 2010-11-12 2016-02-04 Roche Innovation Center Copenhagen A/S Compositions and methods for treating androgen receptor dependent disorders including cancers
US8309768B2 (en) 2010-11-29 2012-11-13 The Ohio State University Research Foundation FTY720-derived anticancer agents
US8546397B2 (en) 2010-12-20 2013-10-01 The Ohio State University Research Foundation DNA methylation inhibitors
US10640464B2 (en) 2011-01-03 2020-05-05 The William M. Yarbrough Foundation Use of isothiocyanate functional surfactants as Nrf2 inducers to treat epidermolysis bullosa simplex and related diseases
US9962361B2 (en) 2011-01-03 2018-05-08 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US10273205B2 (en) 2011-01-03 2019-04-30 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating isothiocyanate functional surfactants and associated methods for treating biofilms
US10647668B2 (en) 2011-01-03 2020-05-12 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US11279674B2 (en) 2011-01-03 2022-03-22 The William M. Yarbrough Foundation Isothiocyanate functional surfactant and associated method of use
US11407713B2 (en) 2011-01-03 2022-08-09 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US8933119B2 (en) 2011-01-03 2015-01-13 The William M. Yarbrough Foundation Method for treating phytophotodermatitis
US10308599B2 (en) 2011-01-03 2019-06-04 The William M. Yarbrough Foundation Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use
US8865765B2 (en) 2011-01-12 2014-10-21 The William M. Yarbrough Foundation Method for treating eczema
EA034451B1 (ru) 2011-02-07 2020-02-10 Байоджен Ма Инк. Модуляторы s1p
US9532969B2 (en) 2011-02-08 2017-01-03 The William M. Yarbrough Foundation Method for treating psoriasis
US9383364B2 (en) 2011-03-07 2016-07-05 University Of Louisville Research Foundation, Inc. Predictive marker of DNMT1 inhibitor therapeutic efficacy and methods of using the marker
US9616064B2 (en) 2011-03-30 2017-04-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Rho kinase inhibitors and methods of use
US10059746B2 (en) 2011-04-04 2018-08-28 University Of Iowa Research Foundation Methods of improving vaccine immunogenicity
EP2694079B1 (de) 2011-04-06 2018-01-17 Rutgers, The State University of New Jersey Polymere und verfahren zur schmerzbehandlung
EP2699242B1 (de) 2011-04-19 2017-11-01 Alfama, Inc. Kohlenmonoxidfreisetzende moleküle und ihre verwendungen
WO2012145678A1 (en) 2011-04-20 2012-10-26 Regents Of The University Of Minnesota Anti-cancer and anti-inflammatory parthenolide compounds
WO2012177770A1 (en) 2011-06-20 2012-12-27 Rutgers, The State University Of New Jersey Bipartite inhibitors of bacterial rna polymerase
US9133230B2 (en) 2011-06-21 2015-09-15 The United States Of America As Represented By The Department Of Veterans Affairs Hydrazone derivatives having potent antitumor activity toward multi-drug resistant tumor cells
EP2729483A1 (de) 2011-07-08 2014-05-14 Regents Of The University Of Minnesota Glutathionanaloga und ihre verwendung
JP6134710B2 (ja) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドAlfama,Inc. 一酸化ルテニウム放出分子およびその使用
AU2012287103B2 (en) 2011-07-22 2017-03-30 University Of Louisville Research Foundation, Inc. Anti-biofilm compounds
CA2843417C (en) 2011-07-29 2018-08-21 Medivation Prostate Therapeutics, Inc. Treatment of breast cancer
US20150017091A1 (en) 2011-08-18 2015-01-15 Cornell University Detection and treatment of metastatic disease
WO2013028866A1 (en) 2011-08-24 2013-02-28 Regents Of The University Of Minnesota Therapeutic compounds and methods
US9034336B2 (en) 2011-08-30 2015-05-19 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
CA2846860A1 (en) 2011-08-30 2013-03-07 Wayne State University Therapeutic compounds and methods
CA2846676C (en) 2011-09-08 2020-06-23 Western University Of Health Sciences Cystine coupled targeting liposomes
CA2848540A1 (en) 2011-09-15 2013-03-21 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Therapeutic compounds
ES2701748T3 (es) * 2011-11-04 2019-02-25 Enceladus Pharmaceuticals B V Corticoesteroides liposomales para el tratamiento de trastornos inflamatorios en humanos
US9828326B2 (en) * 2011-12-27 2017-11-28 Northeast Ohio Medical University Amooranin compounds and analogs thereof and related methods of use
WO2013103969A1 (en) 2012-01-05 2013-07-11 Rutgers, The State University Of New Jersey Antibacterial agents: phloroglucinol derivatives
WO2013106572A1 (en) 2012-01-11 2013-07-18 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona Acting For And On Behalf Of Arizona State University Bispecific antibody fragments for neurological disease proteins and methods of use
US9822108B2 (en) 2012-01-13 2017-11-21 Rutgers, The State University Of New Jersey Antimicrobial agents
US9333242B2 (en) 2012-01-19 2016-05-10 Hybrid Medical, Llc Topical therapeutic formulations
WO2013109972A2 (en) 2012-01-20 2013-07-25 Regents Of The University Of Minnesota Therapeutic compounds
JP5836402B2 (ja) * 2012-01-25 2015-12-24 Sbiファーマ株式会社 腫瘍診断剤
WO2013113102A1 (en) 2012-02-01 2013-08-08 The Governors Of The University Of Alberta USE OF PDGFR-α AS DIAGNOSTIC MARKER FOR PAPILLARY THYROID CANCER
US20130195752A1 (en) 2012-02-01 2013-08-01 Regents Of The University Of Minnesota Functionalized nanoparticles and methods of use thereof
US9839634B2 (en) 2012-02-06 2017-12-12 Rutgers, The State University Of New Jersey Antibacterial agents: combination of a rifamycin and a switch region inhibitor
US9688668B2 (en) 2012-02-08 2017-06-27 University Of Virginia Patent Foundation Long chain base sphingosine kinase inhibitors
AU2013225682B2 (en) 2012-03-02 2016-04-14 The Board Of Trustees Of The University Of Illinois Potent anticancer activity via dual compound activation
CA2866021C (en) 2012-03-06 2020-09-22 The Board Of Trustees Of The University Of Illinois Procaspace 3 activation by pac-1 combination therapy
AU2013230985B2 (en) 2012-03-06 2016-05-12 The Board Of Trustees Of The University Of Illinois Procaspase combination therapy for glioblastoma
US9475783B2 (en) 2012-03-21 2016-10-25 Rutgers, The State University Of New Jersey Antimicrobial agents
US9187446B2 (en) 2012-03-22 2015-11-17 Rutgers, The State University Of New Jersey Antibacterial agents: sidechainfluorinated myxopyronin derivatives
CN104583203B (zh) 2012-03-26 2017-06-13 衣阿华大学研究基金会 Schweinfurthin类似物
US9272016B2 (en) 2012-04-20 2016-03-01 University Of Iowa Research Foundation Methods to enhance RNAi oligonucleotide delivery to respiratory epithelial cells
CA2872751A1 (en) 2012-05-07 2013-11-14 The Regents Of The University Of California Oxysterol analogue oxy133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis
RU2014148918A (ru) 2012-05-21 2016-07-10 Кеми Нутра Инк. Композиции и способы повышения выносливости и мышечной массы
US20130338114A1 (en) 2012-05-23 2013-12-19 Chemi Nutra Compositions for increasing strength, muscle mass, and lean body mass
EP2854834A4 (de) 2012-05-30 2016-05-18 Biostrategies LC Pflanzenlektine als träger entsprechender wirkstoffe in tierischen und menschlichen zellen
US9434681B2 (en) 2012-06-15 2016-09-06 Rutgers, The State University Of New Jersey Macromolecules for treating atherosclerosis
CA2877146C (en) 2012-06-18 2020-10-20 Dart Neuroscience (Cayman) Ltd Substituted thiophene- and furan-fused azolopyrimidine-5-(6h)-one compounds
WO2013192352A1 (en) 2012-06-19 2013-12-27 Rutgers, The State University Of New Jersey Antibacterial agents: aryl myxopyronin derivatives
EP2863910B1 (de) 2012-06-20 2020-03-11 University Of Virginia Patent Foundation Zusammensetzungen und verfahren zur regulierung einer glucosehomöostase und einer insulinwirkung
AU2013286683B2 (en) 2012-07-05 2017-07-13 University Of Iowa Research Foundation Therapeutic bisphosphonates
WO2014011624A2 (en) 2012-07-10 2014-01-16 Xpd Holdings Llc Stabilized multi-functional antioxidant compounds and methods of use
US9605002B2 (en) 2012-07-18 2017-03-28 University Of Notre Dame Du Lac 5,5-heteroaromatic anti-infective compounds
WO2014018671A1 (en) 2012-07-24 2014-01-30 Regents Of The University Of Minnesota Therapeutic compounds for the treatment of cancer
US10080734B2 (en) 2012-07-26 2018-09-25 The William M. Yarbrough Foundation Method for treating autism and other neurodevelopmental disorders
US10335387B2 (en) 2012-07-26 2019-07-02 The William M. Yarbrough Foundation Method for treating infectious diseases with isothiocyanate functional compounds
US10434081B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Inhibitors of macrophage migration inhibitory factor
US9949943B2 (en) 2012-07-26 2018-04-24 The William M. Yarbrough Foundation Method for treating neurodegenerative diseases
US10434082B2 (en) 2012-07-26 2019-10-08 The William M. Yarbrough Foundation Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms
US9839621B2 (en) 2012-07-26 2017-12-12 The William M. Yarbrough Foundation Method for treating bladder cancer
WO2014018874A1 (en) 2012-07-26 2014-01-30 The William M. Yarbrough Foundation Method for treating skin cancer
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
TWI616430B (zh) 2012-07-27 2018-03-01 百健Ma公司 Atx調節劑
MX367879B (es) 2012-08-01 2019-09-10 Lewis And Clark Pharmaceuticals Inc N-alquil 2-(disustituido)alquiladenosin-5-uronamidas como agonistas a2a.
US9249116B2 (en) 2012-08-03 2016-02-02 The Board Of Trustees Of The University Of Illinois Enzyme-activating compounds and compositions
US9499485B2 (en) 2012-08-06 2016-11-22 Biogen Ma Inc. Compounds that are S1P modulating agents and/or ATX modulating agents
EP2879674B1 (de) 2012-08-06 2017-11-22 Biogen MA Inc. Verbindungen als s1p-modulierende mittel und/oder atx-modulierende mittel
WO2014028025A1 (en) 2012-08-16 2014-02-20 University Of Southern California Compositions and methods for treating myotonic dystrophy type 1
ES2877570T3 (es) 2012-08-22 2021-11-17 Univ Cornell Métodos para inhibir fascina
WO2014039860A2 (en) 2012-09-07 2014-03-13 University Of Louisville Research Foundation, Inc. Compositions and methods for modulating dnmt1 inhibitor activity
WO2014043252A2 (en) 2012-09-11 2014-03-20 Rutgers, The State University Of New Jersey Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinones
WO2014041546A1 (en) 2012-09-13 2014-03-20 Ben-Gurion University Of The Negev Research And Development Authority Diagnostic agents with enhanced sensitivity/specificity
CN105744958B (zh) 2012-09-13 2019-11-05 长庚医疗财团法人林口长庚纪念医院 新颖医药组成物及其用途
NZ744456A (en) 2012-09-26 2019-09-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
WO2014059021A1 (en) 2012-10-09 2014-04-17 Case Western Reserve University Rod-shaped plant virus nanoparticles as imaging agent platforms
AU2013329171A1 (en) 2012-10-10 2015-04-30 Arizona Board Of Regents, On Behalf Of Arizona State University Multifunctional radical quenchers
US20140120057A1 (en) 2012-10-25 2014-05-01 Rutgers, The State University Of New Jersey Polymers and methods thereof for wound healing
US9296730B2 (en) 2012-10-26 2016-03-29 Regents Of The University Of Minnesota Aurora kinase inhibitors
WO2014070774A1 (en) 2012-10-29 2014-05-08 Southern Methodist University Methods of generating beta-lactamase resistant carbapenem compounds
PL2917212T3 (pl) 2012-11-08 2020-03-31 Rutgers, The State University Of New Jersey Środki przeciwdrobnoustrojowe
US9701638B2 (en) 2012-11-09 2017-07-11 Rutgers, The State University Of New Jersey Therapeutic hydroxyquinolones
JP2016504284A (ja) 2012-11-16 2016-02-12 バイオクリスト ファーマスーティカルズ,インコーポレイテッドBiocryst Pharmaceuticals,Inc. 抗ウイルス性アザ糖を含有するヌクレオシド
WO2014078857A1 (en) 2012-11-19 2014-05-22 Regents Of The University Of Minnesota Ergoline derivatives as dopamine receptor modulators
ES2749467T3 (es) 2012-11-20 2020-03-20 Biogen Ma Inc Agentes moduladores de S1p y/o ATX
US9850206B2 (en) 2012-11-20 2017-12-26 Biogen Ma Inc. S1P and/or ATX modulating agents
US9522131B2 (en) 2013-01-11 2016-12-20 Wisconsin Alumni Research Foundation Tannin-containing gastrointestinal formulations and methods of use
PL2945628T3 (pl) 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
CA2899322A1 (en) 2013-01-29 2014-08-07 Biogen Ma Inc. S1p modulating agents
US9981043B2 (en) 2013-02-08 2018-05-29 Regents Of The University Of Minnesota Analgesic conjugates
KR20150119188A (ko) 2013-02-15 2015-10-23 리젠츠 오브 더 유니버시티 오브 미네소타 입자 기능화
JP2016510749A (ja) 2013-03-05 2016-04-11 ユニヴァーシティー オブ ノートル ダム デュ ラック キナゾリノン抗生物質
JP6282721B2 (ja) 2013-03-14 2018-02-21 ダート・ニューロサイエンス・(ケイマン)・リミテッド Pde4阻害剤としての置換ピリジン及びピラジン化合物
WO2014158916A1 (en) 2013-03-14 2014-10-02 Dart Neuroscience, Llc Substituted naphthyridine and quinoline compounds as mao inhibitors
JP2016519672A (ja) 2013-03-15 2016-07-07 ジェネンテック, インコーポレイテッド ブロモドメイン含有タンパク質brd7およびbrd9の阻害によるth2媒介性疾患の治療
US9617282B2 (en) 2013-03-15 2017-04-11 Biogen Ma Inc. Macrocyclic compounds as IRAK4 inhibitors for the treatment of inflammatory diseases
WO2014152725A1 (en) 2013-03-15 2014-09-25 Biogen Idec Ma Inc. S1p and/or atx modulating agents
MX388587B (es) 2013-03-15 2025-03-20 Rexahn Pharmaceuticals Inc Procedimiento para la preparacion de 4-amino-1-((1s,4r,5s)-2-fluoro-4,5-dihidroxi-3-hidroximetil-ciclopent-2-enil)-1h-pirimidin-2-ona.
US9387250B2 (en) 2013-03-15 2016-07-12 Rutgers, The State University Of New Jersey Therapeutic compositions for bone repair
JP2016517888A (ja) 2013-05-02 2016-06-20 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 骨選択的骨形成のオキシステロール骨標的薬剤
JP6208332B2 (ja) 2013-05-06 2017-10-04 カオシュン・チャン・グン・メモリアル・ホスピタル 医薬組成物及びその用途
WO2014194055A1 (en) 2013-05-29 2014-12-04 Rutgers, The State University Of New Jersey Antioxidant-based poly(anhydride-esters)
US9452217B2 (en) 2013-06-22 2016-09-27 Nitor Therapeutics Methods for potentiating immune response for the treatment of infectious diseases and cancer
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
EP3027202A1 (de) 2013-08-01 2016-06-08 Regents of the University of Minnesota Wirkstofffreisetzungsverfahren
CN104341504B (zh) 2013-08-06 2017-10-24 百奥泰生物科技(广州)有限公司 双特异性抗体
EP3030241A4 (de) 2013-08-06 2019-06-19 H. Lee Moffitt Cancer Center And Research Institute, Inc. Inhibitoren einer ack1/tnk2.tyrosinkinase
WO2015038966A1 (en) 2013-09-12 2015-03-19 Regents Of The University Of Minnesota Semi-solid delivery systems
US9878045B2 (en) 2013-10-15 2018-01-30 Regents Of The University Of Minnesota Triorthogonal reagents for dual protein conjugation
CN112353791B (zh) 2013-11-11 2025-02-25 夸利蒂赫布丘蒂克斯公司 卡瓦衍生的治疗性化合物及其使用方法
US9387199B2 (en) 2013-11-12 2016-07-12 University Of Virginia Patent Foundation Compositions and methods for treating clostridium infection and preventing recurrence of infection
US9339482B2 (en) 2013-11-22 2016-05-17 Regents Of The University Of Minnesota Methods to treat dysregulated blood glucose disorders
US9315523B2 (en) 2013-12-06 2016-04-19 Rutgers, The State University Of New Jersey Cyclic dinucleosides
WO2015109318A2 (en) 2014-01-17 2015-07-23 Arizona Board Of Regents, A Body Corporate Of The State Of Arizona, Acting For And On Behalf Of Arizona State University Therapeutic methods
WO2015120320A1 (en) 2014-02-06 2015-08-13 Rutgers, The State University Of New Jersey Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
WO2015123654A1 (en) 2014-02-17 2015-08-20 The Cleveland Clinic Foundation Amine passivated nanoparticles for cancer treatment and imaging
US9573946B2 (en) 2014-02-20 2017-02-21 Novita Pharmaceuticals, Inc. Compounds and methods for inhibiting fascin
WO2015130805A1 (en) 2014-02-26 2015-09-03 Arizona Board Of Regents On Behalf Of Arizona State University Dna gridiron compositions and methods
US9908856B2 (en) 2014-02-26 2018-03-06 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10272055B2 (en) 2014-03-06 2019-04-30 Regents Of The University Of Minnesota Therapeutic compounds and methods
KR102736869B1 (ko) 2014-03-07 2024-12-02 바이오크리스트파마슈티컬즈,인코포레이티드 인간 혈장 칼리크레인 저해제
US10197575B2 (en) 2014-03-31 2019-02-05 H. Lee Moffitt Cancer Center And Research Institute, Inc. Stabilized peptoid-peptide hybrids and uses thereof
US10266603B2 (en) 2014-04-18 2019-04-23 The Governors Of The University Of Alberta Targeted therapy to restore radioactive iodine transport in thyroid cancer
HUE057317T2 (hu) 2014-04-23 2022-04-28 Dart Neuroscience Llc Helyettesített [1,2,4]triazolo[1,5-A]pirimidin-7-IL vegyületeket tartalmazó készítmények mint PDE2 inhibítorok
EP3134406A1 (de) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituierte 2,4,5,6-tetrahydropyrrolo [ 3,4-c ] pyrazol-und 4,5,6,7-tetrahydro-2 h-pyrazolo [ 4,3-c ] pyridinverbindungen als glyt1-inhibitoren
US9556113B2 (en) 2014-04-29 2017-01-31 The South Dakota Board Of Regents Combination uses of dichloroacetate and oxamate, and their prodrugs, for cancer treatment
US9987299B2 (en) 2014-05-05 2018-06-05 University Of Iowa Research Foundation Methods of improving RNAi in well-differentiated airway epithelia
WO2015188051A1 (en) 2014-06-06 2015-12-10 Biogen Ma Inc. Atx modulating agents
US10023521B2 (en) 2014-06-13 2018-07-17 Rutgers, The State University Of New Jersey Process and intermediates for preparing poly(anhydride-esters)
WO2015195563A1 (en) 2014-06-16 2015-12-23 Rutgers, The State University Of New Jersey Antibacterial agents
NL2013661B1 (en) 2014-10-21 2016-10-05 Ablynx Nv KV1.3 Binding immunoglobulins.
US9737598B2 (en) 2014-06-30 2017-08-22 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
EP3166626B1 (de) 2014-07-11 2021-04-28 Biostrategies LC Materialien und verfahren zur behandlung von leiden in zusammenhang mit sulfataseenzymen
US10246456B2 (en) 2014-07-18 2019-04-02 Biogen Ma Inc. IRAK4 inhibiting agents
KR20170042778A (ko) * 2014-08-19 2017-04-19 고꾸리츠 다이가꾸 호우징 오까야마 다이가꾸 면역 세포의 기능 증강 방법 및 면역 세포의 다기능성 평가 방법
AU2015304860B2 (en) 2014-08-19 2020-07-16 Hsiri Therapeutics, LLC Antibacterial sideromycins
WO2016037171A1 (en) 2014-09-05 2016-03-10 The Cleveland Clinic Foundation Flavonoid il-17a inhibitors
US9630905B2 (en) 2014-09-08 2017-04-25 Rutgers, The State University Of New Jersey Amphiphilic macromolecules and methods of use thereof
EP3191086B1 (de) 2014-09-11 2021-05-05 University of Iowa Research Foundation Thymol und carvacol zur verwendung in der medizin
US10328114B2 (en) 2014-10-28 2019-06-25 University Of Iowa Research Foundation Lung injury repair compositions and methods
EP3215500A1 (de) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituierte azetidinylverbindungen als glyt1-inhibitoren
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學(開曼)有限責任公司 作為pde2抑制劑之經取代的5-甲基-[1,2,4]三唑并[1,5-a]嘧啶-2-胺化合物
IL252192B2 (en) * 2014-11-10 2024-03-01 Del Mar Pharmaceuticals Dianhydrogalactitol together with radiation to treat non-small-cell carcinoma of the lung and glioblastoma multiforme
US10920195B2 (en) 2014-11-13 2021-02-16 University Of Iowa Research Foundation Methods to generate epithelial cells
CA2968145C (en) 2014-11-17 2023-06-27 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
AU2015366284B2 (en) 2014-12-19 2021-07-22 Ablynx N.V. Cysteine linked nanobody dimers
CN107405388A (zh) 2015-01-08 2017-11-28 衣阿华大学研究基金会 用于体内关节软骨再生的方法
WO2016115516A1 (en) 2015-01-16 2016-07-21 University Of Iowa Research Foundation Methods to prevent or treat periodontitis or peri-implantitis
AU2016220153B2 (en) 2015-02-17 2020-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US10472340B2 (en) 2015-02-17 2019-11-12 Arizona Board Of Regents On Behalf Of Arizona State University Substituted phenothiazines as mitochondrial agents
WO2016140978A1 (en) 2015-03-03 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2016140979A1 (en) 2015-03-03 2016-09-09 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
MX2017011237A (es) 2015-03-06 2017-11-28 Cleveland Clinic Found Alteracion del metabolismo de esteroides para el tratamiento de enfermedades dependientes de esteroides.
US9926261B2 (en) 2015-03-10 2018-03-27 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
US9950993B2 (en) 2015-03-13 2018-04-24 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
WO2016164898A1 (en) 2015-04-10 2016-10-13 Rutgers, The State University Of New Jersey Kojic acid polymers
US20180126013A1 (en) 2015-05-06 2018-05-10 H.Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapeutic and companion imaging agents to target mc1r
WO2016179587A1 (en) 2015-05-07 2016-11-10 Kuality Herbceutics Llc Therapeutic compounds and methods of use thereof
US20180125780A1 (en) 2015-05-15 2018-05-10 The Methodist Hospital System Implantable nanochannel delivery devices
WO2016187264A1 (en) 2015-05-18 2016-11-24 The Arizona Board Of Regents On Behalf Of The University Of Arizona Enhanced melanoma cancer prevention by novel melanotropins
IL256111B2 (en) 2015-06-05 2023-09-01 Univ Illinois Treatment of pac combinations
TW201710503A (zh) 2015-06-12 2017-03-16 長庚醫療財團法人林口長庚紀念醫院 新穎多核苷酸、載體、醫藥組成物以及其用途
US11369569B2 (en) 2015-06-15 2022-06-28 University Of Virginia Patent Foundation Target-specific delivery of therapeutic agents
US10308663B2 (en) 2015-06-16 2019-06-04 University Of Virginia Patent Foundation Inhibitors of PTP4A3 for the treatment of cancer
US9399039B1 (en) 2015-06-30 2016-07-26 University Of South Florida Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use
WO2017011686A1 (en) 2015-07-14 2017-01-19 University Of Iowa Research Foundation Fluorescent prodrugs
EP3322485B1 (de) 2015-07-16 2020-07-01 Case Western Reserve University Pflanzenviruspartikel zur freisetzung von antimitotika
AU2016298175B2 (en) 2015-07-28 2022-01-06 University Of Iowa Research Foundation Compositions and methods of treating cancer
CN108348779A (zh) 2015-08-02 2018-07-31 H·李·莫菲特癌症中心研究有限公司 Ack1/tnk2酪氨酸激酶的抑制剂
WO2017027883A1 (en) 2015-08-13 2017-02-16 San Diego State University Research Foundation Atropisomerism for increased kinase inhibitor selectivity
CA2997545C (en) 2015-09-04 2022-01-11 Janssen Pharmaceutica Nv Therapeutic compounds for pain and synthesis thereof
DK4019022T3 (en) 2015-10-01 2024-02-19 Biocryst Pharm Inc Human plasma kallikrein inhibitors
WO2017066428A1 (en) 2015-10-13 2017-04-20 H. Lee Moffitt Cancer Center & Research Institute, Inc. Brd4-kinase inhibitors as cancer therapeutics
WO2017070328A1 (en) 2015-10-20 2017-04-27 The Cleveland Clinic Foundation STIMULATION OF 11β-HSD2 EXPRESSION TO IMPROVE HORMONAL THERAPY OF STEROID-DEPENDENT DISEASE
AU2016349897B2 (en) 2015-11-03 2021-11-04 Regents Of The University Of Minnesota CD200 inhibitors and methods of use thereof
JP7017509B2 (ja) 2015-11-20 2022-02-08 センワ バイオサイエンシズ インコーポレイテッド がんを治療するための四環式キノロン類似体の併用療法
US9957282B2 (en) 2015-12-14 2018-05-01 Senhwa Biosciences, Inc. Crystalline forms of quinolone analogs and their salts
US9980951B2 (en) 2015-12-17 2018-05-29 University Of Iowa Research Foundation Image guided therapy for cancer
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
US11427561B2 (en) 2016-01-20 2022-08-30 Biogen Ma Inc. IRAK4 inhibiting agents
TWI747873B (zh) 2016-02-01 2021-12-01 美商百歐克斯製藥公司 苯并吡唑化合物及其類似物
US20190046637A1 (en) 2016-03-01 2019-02-14 Biostrategies LC Materials and methods for mitigating immune-sensitization
WO2017156527A1 (en) 2016-03-11 2017-09-14 H. Lee Moffitt Cancer Center And Research Institute, Inc. Aurora kinase and janus kinase inhibitors for prevention of graft versus host disease
BR112018068906A2 (pt) 2016-03-16 2019-01-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo
US11529340B2 (en) 2016-03-22 2022-12-20 Regents Of The University Of Minnesota Combination for treating pain
US10759740B2 (en) 2016-03-24 2020-09-01 Rutgers, The State University Of New Jersey Antibacterial agents
JP2019515025A (ja) 2016-04-04 2019-06-06 ラトガース ザ ステイト ユニバーシティー オブ ニュージャージー トポイソメラーゼ毒
US10551384B2 (en) 2016-04-07 2020-02-04 Rutgers, The State University Of New Jersey MTOR kinase mutations and methods of use thereof
EP4230713A1 (de) 2016-04-18 2023-08-23 Gene Pool Technologies, Inc. Isolierung von pflanzenextrakten
RU2018142711A (ru) 2016-05-04 2020-06-04 Х. Ли Моффитт Кэнсер Сентер Энд Рисёч Инститьют, Инк. Средство для целенаправленного воздействия на дельта-опиоидный рецептор для молекулярной визуализации и иммунотерапии рака
US11697851B2 (en) 2016-05-24 2023-07-11 The Regents Of The University Of California Early ovarian cancer detection diagnostic test based on mRNA isoforms
KR102434879B1 (ko) 2016-05-26 2022-08-22 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 폐혈관 질환 치료용 조성물 및 방법
US10899793B2 (en) 2016-05-27 2021-01-26 Regents Of The University Of Minnesota Melanocortin ligands and methods of use thereof
US11351270B2 (en) 2016-06-07 2022-06-07 University Of Iowa Research Foundation Junctophilin-2 fragments and uses therefor
RU2019101420A (ru) 2016-06-20 2020-07-21 Ратгерс, Де Стейт Юниверсити Оф Нью Джерси Терапевтические соединения
AU2017281940C1 (en) 2016-06-24 2024-11-07 University Of Iowa Research Foundation Compositions and methods of treating melanoma
US10918647B2 (en) 2016-07-26 2021-02-16 University Of Southern California Selective bromodomain inhibition of fungal Bdf1
AU2017306558B2 (en) 2016-08-03 2024-09-19 University Of South Florida Reelin compositions for treatment of neurological disorders
US20180037909A1 (en) 2016-08-04 2018-02-08 Chang Gung Memorial Hospital, Linkou Modified cancer cell lines and uses thereof
US11390605B2 (en) 2016-08-25 2022-07-19 Arizona Board Of Regents On Behalf Of Arizona State University Substituted pyrimidine compounds as multifunctional radical quenchers and their uses
CA3034885A1 (en) 2016-08-31 2018-03-08 Dart Neuroscience, Llc Hydroxynorketamine derivatives for the treatment of disorders
AU2017347549A1 (en) 2016-10-17 2019-05-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
US11124541B2 (en) 2016-10-18 2021-09-21 Regents Of The University Of Minnesota Chimeric melanocortin ligands and methods of use thereof
CA3041058A1 (en) 2016-10-31 2018-05-03 Biocryst Pharmaceuticals, Inc. Carbamimidoylphenylcarbamoyl derivatives and pharmaceutical compositions thereof useful as kallikrein inhibithors
US11071747B2 (en) 2016-11-29 2021-07-27 University Of Iowa Research Foundation Use of NAD precursors for breast enhancement
MX2019006278A (es) 2016-11-29 2019-08-21 Univ Iowa Res Found Uso de precursores de nad para mejorar la salud materna y/o salud de la descendencia.
US20180194824A1 (en) 2016-12-14 2018-07-12 University Of Iowa Research Foundation Musclin peptides and methods of use thereof
CN114989205A (zh) 2016-12-22 2022-09-02 卡里塞拉生物科学股份公司 用于抑制精氨酸酶活性的组合物和方法
AR110590A1 (es) 2016-12-27 2019-04-10 Biogen Ma Inc Activador de nrf2
KR102590848B1 (ko) 2016-12-28 2023-10-19 다트 뉴로사이언스, 엘엘씨 Pde2 억제제로서 치환된 피라졸로피리미디논 화합물
US10710957B2 (en) 2017-01-09 2020-07-14 University Of Central Florida Research Foundation, Inc. Motuporamine derivatives as antimicrobial agents and antibiotic enhancers against resistant gram-negative bacteria
US20180230105A1 (en) 2017-01-13 2018-08-16 Regents Of The University Of Minnesota Therapeutic compounds
CA3050255A1 (en) 2017-01-20 2018-07-26 The Regents Of The University Of California Inhibitors of the n-terminal domain of the androgen receptor
US10231947B2 (en) 2017-01-23 2019-03-19 Arizona Board Of Regents On Behalf Of Arizona State University Isochroman compounds and methods of use thereof
US10238655B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Dihydroindene and tetrahydronaphthalene compounds
US10238626B2 (en) 2017-01-23 2019-03-26 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
WO2018140504A1 (en) 2017-01-24 2018-08-02 Patel Manoj K Compositions and methods for blocking sodium channels
WO2018140738A1 (en) 2017-01-30 2018-08-02 Biogen Ma Inc. Nrf 2 activator
US20190389836A1 (en) 2017-01-30 2019-12-26 Biogen Ma Inc. Nrf2 activator
EP3580224B1 (de) 2017-02-07 2022-07-13 Biogen MA Inc. Ask1-hemmende mittel
WO2018150276A2 (en) 2017-02-16 2018-08-23 Universidad San Sebastian The combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological conditions
US11938114B2 (en) 2017-03-10 2024-03-26 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
SG11201908351TA (en) 2017-03-10 2019-10-30 Edmond J Lavoie Indole derivatives as efflux pump inhibitors
WO2018165612A1 (en) 2017-03-10 2018-09-13 Rutgers, The State University Of New Jersey Bacterial efflux pump inhibitors
IL269933B (en) 2017-04-14 2022-07-01 Biogen Ma Inc Benzozapine analogues as inhibitors for proton tyrosine kinase
US10294264B2 (en) 2017-04-21 2019-05-21 Warsaw Orthopedic, Inc. Oxysterol-therapeutic agent derivative for bone healing
US10456401B2 (en) 2017-05-12 2019-10-29 Innovus Pharmaceuticals, Inc. Therapeutic methods and compositions
US10434106B2 (en) 2017-05-19 2019-10-08 Warsaw Orthopedic, Inc. Oxysterol-statin compounds for bone growth
US11896591B2 (en) 2017-05-22 2024-02-13 University Of Virginia Patent Foundation Compositions and methods for preparing and using mitochondrial uncouplers
EP3630109A4 (de) 2017-05-26 2021-03-17 Rutgers, the State University of New Jersey Inhibitoren für bakterielle abflusspumpen
JP7249961B2 (ja) 2017-06-02 2023-03-31 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング Adamts5、mmp13およびアグリカンに結合するポリペプチド
NZ759601A (en) 2017-06-02 2023-06-30 Merck Patent Gmbh Aggrecan binding immunoglobulins
TW202417517A (zh) 2017-06-02 2024-05-01 德商麥克專利有限公司 與mmp13結合之免疫球蛋白
CN118894939A (zh) 2017-06-02 2024-11-05 默克专利股份有限公司 结合adamts的免疫球蛋白
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
EP3641783A4 (de) 2017-06-22 2021-03-10 University Of Virginia Patent Foundation Protonenaktivierte atommedizin
US20180371526A1 (en) 2017-06-23 2018-12-27 Arizona Board Of Regents On Behalf Of Arizona State University Compositions and methods for detecting viral nucleic acids
US10934300B2 (en) 2017-06-23 2021-03-02 San Diego State University (Sdsu) Foundation Atropisomerism for enhanced kinase inhibitor selectivity
WO2019005841A1 (en) 2017-06-26 2019-01-03 Rutgers, The State University Of New Jersey THERAPEUTIC COMPOUNDS AND METHODS FOR TREATING INFECTION
WO2019014305A1 (en) 2017-07-12 2019-01-17 Dart Neuroscience, Llc SUBSTITUTED BENZOXAZOLE AND BENZOFURAN COMPOUNDS AS PDE7 INHIBITORS
CN107446050A (zh) 2017-08-11 2017-12-08 百奥泰生物科技(广州)有限公司 Trop2阳性疾病治疗的化合物及方法
US11186549B2 (en) 2017-08-29 2021-11-30 Rutgers, The State University Of New Jersey Therapeutic indazoles
US11254941B2 (en) 2017-08-30 2022-02-22 Arizona Board Of Regents On Behalf Of Arizona State University RNA nanostructures and methods of making and using RNA nanostructures
CN111757738A (zh) 2017-10-06 2020-10-09 蓝色治疗公司 治疗急性或慢性疼痛的方法
US10702508B2 (en) 2017-10-16 2020-07-07 Aragon Pharmaceuticals, Inc. Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
US11565094B2 (en) 2017-10-17 2023-01-31 The Methodist Hospital System Delivery devices
AU2018368453B2 (en) 2017-11-17 2024-05-30 The Board Of Trustees Of The University Of Illinois Cancer therapy by degrading dual MEK signaling
EP3710467A4 (de) 2017-11-17 2021-08-04 Cytogel Pharma, LLC Polymere agonisten von mu-opioid-rezeptoren
US11465963B2 (en) 2017-11-21 2022-10-11 Biogen Ma Inc. Tetrahydronaphthalene derivatives useful as Nrf2 activators
DK3717488T3 (da) 2017-11-27 2021-12-13 Dart Neuroscience Llc Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
EP3716956B1 (de) 2017-11-29 2024-06-26 The Cleveland Clinic Foundation Antitumor-tet2-modulierende verbindungen
WO2019108285A1 (en) 2017-11-30 2019-06-06 Cytogel Pharma, Llc Novel analgesic pharmaceutical formulations and uses thereof
US20200397808A1 (en) 2017-12-07 2020-12-24 The Cleveland Clinic Foundation Treatment of steroid-resistant disease using an anthocyanin and a corticosteroid
WO2019140140A1 (en) 2018-01-10 2019-07-18 Arizona Board Of Regents On Behalf Of Arizona State University Rna-nanostructured double robots and methods of use thereof
US10738093B2 (en) 2018-01-25 2020-08-11 The Hong Kong University Of Science And Technology Discovery of cationic nonribosomal peptides as Gram-negative antibiotics through global genome mining
CN112118837B (zh) 2018-02-13 2024-07-09 罗格斯新泽西州立大学 抗菌剂:o-烷基氘化派洛宁
CN112334133A (zh) 2018-02-15 2021-02-05 生华生物科技股份有限公司 喹诺酮类似物及其盐、组合物及其使用方法
US11890352B2 (en) 2018-02-27 2024-02-06 University Of Virginia Patent Foundation Plectin-targeted liposomes/PARP inhibitor in the treatment of cancer
WO2019168866A1 (en) 2018-02-28 2019-09-06 Dart Neuroscience, Llc Substituted cyclohexyl compounds as nop inhibitors
WO2019173507A1 (en) 2018-03-06 2019-09-12 Rutgers, The State University Of New Jersey Antibacterial agents : arylalkylcarboxamido phloroglucinols
WO2019178267A2 (en) 2018-03-13 2019-09-19 University Of Iowa Research Foundation Inductive regeneration of the airway by transcriptional factor modulation of glandular myoepithelial stem cells
JP7453916B2 (ja) 2018-03-14 2024-03-21 バイオジェン・エムエイ・インコーポレイテッド O-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グリコピラノシダーゼ阻害剤
TWI873092B (zh) 2018-04-06 2025-02-21 美商百歐克斯製藥公司 取代的苯并呋喃、苯并吡咯、苯并噻吩及結構相關的補體抑制劑
CA3095515A1 (en) 2018-04-10 2019-10-17 Cellectar Biosciences, Inc. Phospholipid-flavagline conjugates and methods of using the same for targeted cancer therapy
US11708376B2 (en) 2018-04-20 2023-07-25 Virginia Tech Intellectual Properties, Inc. Substituted imidazo[4,5-b]pyridines, imidazo[4,5-b]pyrazines, and oxazolo[4,5- b]pyrazines as mitochondrial uncouplers
WO2020036654A2 (en) 2018-04-27 2020-02-20 Arizona Board Of Regents On Behalf Of Arizona State University Highly knotted molecular topologies from single-stranded nucleic acids
EP3793994B1 (de) 2018-05-14 2023-08-23 Biogen MA Inc. Hemmende mittel für bruton-tyrosinkinase
EP3810641A4 (de) 2018-06-19 2022-07-13 H. Lee Moffitt Cancer Center And Research Institute, Inc. Durch onkolytisches virus oder antigenpräsentierende zellen vermittelte krebstherapie unter verwendung von typ-i-interferon und cd40-ligand
WO2020006031A1 (en) 2018-06-27 2020-01-02 Biogen Ma Inc. Ask1 inhibiting agents
WO2020014118A1 (en) 2018-07-09 2020-01-16 Taiwan Liposome Co., Ltd. Methods to reduce complications of intra-articular steroid
CN112512589A (zh) 2018-07-11 2021-03-16 H·李·莫菲特癌症中心研究有限公司 二聚体免疫调节化合物对抗基于cereblon的机制
US10898460B1 (en) 2018-07-20 2021-01-26 University Of South Florida Leishmania inhibitors
US11987568B2 (en) 2018-08-03 2024-05-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Allosteric inhibitor of WEE1 kinase
EP3833342A4 (de) 2018-08-09 2022-07-13 The Board of Trustees of the University of Illinois Imidazotetrazinverbindungen
JP2021534152A (ja) 2018-08-14 2021-12-09 バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. Ask1阻害剤
EP3837265B1 (de) 2018-08-14 2023-02-22 Biogen MA Inc. Pyridinmakrocyclenverbindungen als ask1-hemmer
US11332499B2 (en) 2018-08-16 2022-05-17 Regents Of The University Of Minnesota Cyclic peptides and methods of use thereof
WO2020037116A1 (en) 2018-08-17 2020-02-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors
US20200085784A1 (en) 2018-09-13 2020-03-19 Minneamrita Therapeutics, LLC Methods to treat fibrosis, nash, and nafld
US12180205B2 (en) 2018-09-19 2024-12-31 Biogen Ma Inc. O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
US11820760B2 (en) 2018-10-15 2023-11-21 Biogen Ma Inc. Crystalline polymorphs of Bruton's tyrosine kinase inhibitors
KR20210078512A (ko) 2018-10-17 2021-06-28 선스테이트 바이오사이언시즈, 엘엘씨 치료 효과 향상을 위한 단일 단백질-캡슐화된 약제
WO2020081918A2 (en) 2018-10-18 2020-04-23 H. Lee Moffitt Cancer Center And Research Institute, Inc. Βeta-catenin and b-cell lymphoma 9 (bcl9) inhibitors
US12600710B2 (en) 2018-10-18 2026-04-14 Lee Moffitt Cancer Center and Research Institute, Inc. Beta-catenin and b-cell lymphoma 9 (BCL9) inhibitors
WO2020106454A2 (en) 2018-11-07 2020-05-28 Regents Of The University Of Minnesota Analgesic and anti-addictive compositions for treatment of chronic pain and opioid addiction
WO2020097433A1 (en) 2018-11-09 2020-05-14 The University Of Rochester Methods and systems for treating cancer based on response prediction using light scattering technology
CA3120970A1 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
EP3886848A4 (de) 2018-11-27 2022-08-17 Rutgers, The State University of New Jersey Pharmazeutische verbindungen und therapeutische verfahren
ES2968733T3 (es) 2018-12-05 2024-05-13 Biogen Ma Inc Derivados morfolinilo, piperazinilo, oxazepanilo y diazepanilo útiles como inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa
WO2020118179A1 (en) 2018-12-07 2020-06-11 H. Lee Moffitt Cancer Center And Research Institute, Inc. Peptidomimetic inhibitors of β-catenin/tcf protein–protein interaction
WO2020150149A1 (en) 2019-01-14 2020-07-23 Regents Of The University Of Minnesota Cd200ar ligands for cancer immunotherapy
JP7504898B2 (ja) 2019-02-04 2024-06-24 バイオジェン・エムエイ・インコーポレイテッド 二環式エーテルo-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤
JP7663503B2 (ja) 2019-03-08 2025-04-16 バイオジェン・エムエイ・インコーポレイテッド アゼチジニルo-糖タンパク質-2-アセトアミド-2-デオキシ-3-d-グルコピラノシダーゼ阻害剤
WO2020225779A1 (en) 2019-05-09 2020-11-12 Istituto Pasteur Italia - Fondazione Cenci Bolognetti Rig-i agonists for cancer treatment and immunotherapy
US12240838B2 (en) 2019-05-15 2025-03-04 Biogen Ma Inc. Inhibiting agents for Bruton's tyrosine kinase
US20220241214A1 (en) 2019-06-20 2022-08-04 University Of Iowa Research Foundation Nanoparticles comprising quinone w methides and compositions for use
US20220411398A1 (en) 2019-06-24 2022-12-29 University Of Iowa Research Foundation Jnk inhibitors as anticancer agents
KR20220041846A (ko) 2019-07-31 2022-04-01 바이오크리스트파마슈티컬즈,인코포레이티드 경구 보체 인자 d 억제제에 대한 투약 요법
CN114206839B (zh) 2019-08-06 2025-03-07 拜奥克里斯特制药公司 血浆激肽释放酶抑制剂的生产规模合成
AR120173A1 (es) 2019-10-09 2022-02-02 Biocryst Pharm Inc Inhibidores del factor d del complemento para administración oral
BR112022006739B1 (pt) 2019-10-10 2024-01-23 Cellectar Biosciences, Inc Conjugados fosfolipídio-flavagina e métodos de uso do mesmo para terapia direcionada a câncer
US20220372040A1 (en) 2019-10-25 2022-11-24 Accent Therapeutics, Inc. Mettl3 modulators
AR120324A1 (es) 2019-10-29 2022-02-09 Biogen Ma Inc Inhibidores de o-glucoproteína-2-acetamido-2-deoxi-3-d-glucopiranosidasa espirocíclica
EP4051679B1 (de) 2019-10-30 2025-08-06 Biogen MA Inc. Kondensiertes pyridazin oder pyrimidin als btk-inhibitoren
ES3060629T3 (en) 2019-10-30 2026-03-27 Biogen Ma Inc Condensed bi-heterocycles as inhibiting agents for bruton's tyrosine kinase
EP4081514A1 (de) 2019-12-23 2022-11-02 Biogen MA Inc. Btk-hemmer
US20230053688A1 (en) 2020-01-10 2023-02-23 Cornell University Methods to alter latency in ebv+ malignancies
US12234578B2 (en) 2020-01-29 2025-02-25 Wisconsin Alumni Research Foundation Tannin composite fibers
US12552806B2 (en) 2020-03-20 2026-02-17 University Of Southern California Androgen receptor regulation by small molecule enantiomers
AR121715A1 (es) 2020-04-03 2022-06-29 Biocryst Pharm Inc Pirrolopirimidinaminas como inhibidores del sistema del complemento
EP4153578A1 (de) 2020-05-18 2023-03-29 Salk Institute for Biological Studies Chromen-4-on-derivate, wie z.b. flavone, zur verwendung als ck2-inhibitoren zur behandlung von nervenentzündung
TWI776584B (zh) 2020-07-10 2022-09-01 長庚醫療財團法人林口長庚紀念醫院 β-1腎上腺素受體拮抗劑用於製備減少表皮生長因子受體抑制劑誘導的上皮細胞損傷以及抑制癌細胞的組合物之用途
US11529335B2 (en) 2020-07-31 2022-12-20 University Of Iowa Research Foundation Compositions and methods for treating cancer
TW202220972A (zh) 2020-08-07 2022-06-01 美商百健Ma公司 Btk抑制劑
WO2022047086A1 (en) 2020-08-27 2022-03-03 The Cleveland Clinic Foundation Bioavailable protein disulfide isomerase inhibitors
CA3193736A1 (en) 2020-09-02 2022-03-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Lzk-targeting degraders and methods of use
WO2022055995A1 (en) 2020-09-10 2022-03-17 Arizona Board Of Regents On Behalf Of Arizona State University Therapeutic compounds
US20240051985A1 (en) 2020-10-14 2024-02-15 Accent Therapeutics, Inc. Mettl3 modulators
US20240360157A1 (en) 2021-01-07 2024-10-31 Biogen Ma Inc. Tyk2 inhibitors
CA3208424A1 (en) 2021-02-22 2022-08-25 David M. Ferguson Immunomodulators and immunomodulator conjugates
TWI796023B (zh) 2021-03-10 2023-03-11 長庚醫療財團法人 藥物組合物及其用途
US12303564B2 (en) 2021-03-19 2025-05-20 Wisconsin Alumni Research Foundation Composite chitosan-tannin-active agent compositions and methods of making and using same
EP4313023A1 (de) 2021-04-02 2024-02-07 Biogen MA Inc. Kombinationsbehandlungsverfahren für multiple sklerose
JP7828661B2 (ja) 2021-05-04 2026-03-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 避妊薬の化合物及び方法
TW202309039A (zh) 2021-05-05 2023-03-01 美商百健Ma公司 用於靶向布魯頓氏酪胺酸激酶降解之化合物
EP4358957A1 (de) 2021-06-22 2024-05-01 Dana-Farber Cancer Institute, Inc. (1h-pyrrolo[2,3-b pyridin-1-yl)pyrimidin-2-yl-amino-phenyl-acrylamide inhibitoren von egfr zur verwendung in der behandlung von hirntumoren
US20240293322A1 (en) 2021-06-23 2024-09-05 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator
US20250018046A1 (en) 2021-07-07 2025-01-16 Biogen Ma Inc Compounds for targeting degradation of irak4 proteins
EP4367113A1 (de) 2021-07-07 2024-05-15 Biogen MA Inc. Verbindungen zum targeting des abbaus von irak4-proteinen
KR20240055041A (ko) 2021-09-01 2024-04-26 더 유나이티드 스테이츠 오브 아메리카, 애즈 레프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 혼합 계통 키나제 억제제 및 억제제의 사용 방법
WO2023081237A1 (en) 2021-11-03 2023-05-11 Regents Of The University Of Minnesota Toll-like receptor agonists and antagonists and uses thereof
CN118804915A (zh) 2021-11-10 2024-10-18 渤健马萨诸塞州股份有限公司 Btk抑制剂
WO2023086575A1 (en) 2021-11-12 2023-05-19 Biogen Ma Inc. Btk inhibitors
US20240200078A1 (en) 2021-11-18 2024-06-20 Cornell University Microrna-dependent mrna switches for tissue-specific mrna-based therapies
US20250073322A1 (en) 2021-12-29 2025-03-06 University Of Lowa Research Foundation Cystatin rna compositions for tissue engineering
WO2023220046A1 (en) 2022-05-10 2023-11-16 Biogen Ma Inc. Tyk2 inhibitors
JP2025515728A (ja) 2022-05-10 2025-05-20 バイオジェン・エムエイ・インコーポレイテッド N-メチル-N-((1s,3s)-3-メチル-3-((6-(1-メチル-1H-ピラゾール-4-イル)ピラゾロ[1,5-a]ピラジン-4-イル)オキシ)シクロブチル)アクリルアミドの結晶多形
WO2024006977A1 (en) 2022-07-01 2024-01-04 University Of Southern California Analgesic delta opioid receptor bitopic ligands
CN119731186A (zh) 2022-07-01 2025-03-28 渤健马萨诸塞州股份有限公司 Tyk2抑制剂
WO2024009283A1 (en) 2022-07-07 2024-01-11 University Of Southern California At2 antagonists for non-addictive pain relief
WO2024011214A1 (en) 2022-07-08 2024-01-11 Actio Biosciences, Inc. Therapeutic compounds and methods
CA3267132A1 (en) 2022-09-09 2024-03-14 Regents Of The University Of Minnesota ANTIBODIES DIRECTED AGAINST FENTANYL AND ITS ANALOGUES AND THEIR METHODS OF USE
AU2023376684A1 (en) 2022-11-09 2025-06-19 Merck Patent Gmbh Toll-like receptor 7 agonists as immune-stimulators to elicit the innate antitumor immunity
WO2024112932A1 (en) 2022-11-23 2024-05-30 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
CN120303249A (zh) 2022-12-07 2025-07-11 罗格斯新泽西州立大学 碳酸酐酶抑制剂及其使用方法
EP4676601A1 (de) 2023-03-03 2026-01-14 Deliver Therapeutics, Inc. Proteinkinasehemmer und verwendungen davon
WO2024186579A1 (en) 2023-03-03 2024-09-12 Deliver Therapeutics, Inc. Protein kinase inhibitors and uses thereof
WO2024197165A1 (en) 2023-03-21 2024-09-26 University Of Iowa Research Foundation Broad spectrum antifungal keto-alkyl-pyridinium compounds
WO2024206284A2 (en) 2023-03-27 2024-10-03 Rutgers, The State University Of New Jersey Therapeutic compounds
WO2024211696A1 (en) 2023-04-07 2024-10-10 Biogen Ma Inc. 1h-pyrrolo[2,3-b]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile derivatives as tyrosine kinase 2 (tyk2) inhibitors for the treatment of inflammatory diseases
WO2024226603A1 (en) 2023-04-24 2024-10-31 Regents Of The University Of Minnesota Therapeutic compounds
CN119947715A (zh) 2023-06-22 2025-05-06 艾捷思生物制药有限责任公司 用于增强伤口愈合和皮肤护理的富含多酚的莴苣组合物
WO2025019587A1 (en) 2023-07-18 2025-01-23 Regents Of The University Of Minnesota Senotherapeutic compounds
WO2025043115A1 (en) 2023-08-23 2025-02-27 Taxis Pharmaceuticals, Inc. Bacterial efflux pump inhibitors
WO2025106633A1 (en) 2023-11-15 2025-05-22 Biogen Ma Inc. Tyk2 inhibitors
WO2025259601A1 (en) 2024-06-10 2025-12-18 Nemagen Discoveries, Inc. Carbonic anhydrase enzyme inhibitors and methods of use thereof
WO2026060616A1 (en) 2024-09-20 2026-03-26 Fulcrum Therapeutics, Inc. Phenothiazine and phenoxazine calmodulin inhibitors and methods of use thereof
WO2026076223A1 (en) 2024-10-03 2026-04-09 Regents Of The University Of Minnesota Therapeutic compounds and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148885A (en) * 1973-09-25 1979-04-10 Institut Merieux Immunostimulant medicine
US4594238A (en) * 1980-08-08 1986-06-10 Regents Of University Of Minnesota Inhibition of undesired effect of platinum compounds
US4645661A (en) * 1984-06-29 1987-02-24 St. Jude Children's Research Hospital Method for alleviating cisplatin-induced nephrotoxicity and dithiocarbamate compounds for effecting same

Also Published As

Publication number Publication date
WO1990002550A1 (en) 1990-03-22
EP0433393A1 (de) 1991-06-26
EP0433393B1 (de) 1995-03-15
NZ230622A (en) 1991-09-25
DE68921760D1 (de) 1995-04-20
DK44791D0 (da) 1991-03-12
AU4335589A (en) 1990-04-02
DK44791A (da) 1991-05-10
JPH04500676A (ja) 1992-02-06
EP0433393A4 (en) 1992-01-15
AU623184B2 (en) 1992-05-07
US4938949A (en) 1990-07-03

Similar Documents

Publication Publication Date Title
ATE119771T1 (de) Behandlung von beschädigtem knochenmark und dosierungseinheiten dafür.
EP0139535B1 (de) Zusammensetzungen zur Bekämpfung von Toxaemia
EP0139534B1 (de) Zusammensetzungen zur propylaktischen Behandlung von Osteitis und Osteomyelitis
DE69627651D1 (de) Formulierungen und zusammensetzungen von in wasser schwer löslichen camptothecinderivaten
DK0379979T3 (de)
RU94022479A (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови, фармацевтический препарат
DK98089D0 (da) Medikament-lipid-systemer med lav toxicitet
ATE173627T1 (de) Medizinische zusammensetzung
WO1991002529A2 (en) Product and method for killing abnormal vertebrate cells
US5179096A (en) Therapeutic application of flouroquinolone derivatives
KR910004191A (ko) 신질환치료제
CA2166704C (en) Arsenic medicaments for the treatment of chronic fatigue syndrome
KR960034200A (ko) 항편두통성 인돌릴알킬-피리딘일 및 피리미딘일피페라진의 1,2,5-티아디아졸 유도체
IT1245717B (it) Composto farmaceutico a base di un antocianidina per il trattamento di malattie oftalmiche
IL81337A (en) Heptanoyl-glu-asp-ala-amino acid immunostimulants,process for their preparation and pharmaceutical compositions containing them
DK175078B1 (da) Anvendelse af 15-deoxyspergualin til fremstilling af et lægemiddel til terapeutisk behandling af degenerative sygdomme i centralnervesystemet
KR890003372A (ko) 피리미도[2,1-b] 벤조티아졸 유도체로된 동맥경화 치료의약
KR19990063735A (ko) 1,2,4-벤조트리아진 옥사이드 제제
EP1155694A4 (de) Mittel gegen hiv-infektionen und verfahren zur behandlung von hiv-infektionen
KR100190869B1 (ko) 아목시실린 및 클라부란산을 포함하여 구성되는 수의학적 조성물 및 그를 사용한 치료방법
US3772438A (en) Antibiotic compositions containing coumermycin
US4296124A (en) Pharmaceutical methods
WO2025034972A3 (en) Protective molecules and therapeutic targets for tauopathy
Rose et al. Mercuric cyanide poisoning and its treatment in dogs
KR890014116A (ko) 고혈압치료 혼합물

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties